CHICAGO, IL May 26th, 2023 — Lucence will present promising new data on earlier cancer detection based on AmpliMark, its amplicon-based next generation sequencing technology at the 59th Annual ASCO Meeting in Chicago, June 2-6, 2023.
“Most cancers go undetected until they are at late-stage [1],” said Min-Han Tan, PhD, MBBS, CEO & Medical Director of Lucence. “We look forward to sharing collaborative study results on how earlier cancer detection can be enabled through our liquid biopsy testing.”
Lucence will be presenting the following poster at the ASCO meeting:
#3052 Pek et al. Development and evaluation of a multi-cancer screening (MCS) test for cancers common in Asia. Poster Session: Saturday, June 3rd, from 8.00-11.00AM CDT.
Lucence will share data on a ctDNA mutation-based multi-cancer screening (MCS) liquid biopsy test using its proprietary amplicon-based next-generation sequencing (NGS) testing for detection of cancer-associated alterations. In a cohort of 613 individuals, sensitivity for detection of cancer-associated alterations was 72.7% and specificity was 98.6%. Tissue of origin (TOO) prediction accuracy in an independent 1478-patient cohort was enhanced in 7 of 10 cancers (2 – 50%) by a personalized algorithm including clinico-demographic data. The data demonstrates how amplicon-based NGS supported by a personalized algorithm can support development of a multi-cancer screening test.
Additional key abstracts are available online:
- #3072 Shah et al. Liquid biopsy in combination with PET/CT versus PET/CT alone in diagnosis of lung cancer in small nodules. Poster Session: Saturday, June 3rd, from 8.00-11.00AM CDT.
- #e21072 Heeke et al. Longitudinal tracking of ALK-positive lung cancer from plasma using circulating-tumor RNA and circulating-tumor DNA in the BRIGHTSTAR clinical trial.
- #e13017 Amoako et al. Assessing the utility of liquid biopsy for detecting actionable genetic mutations among indigenous Ghanaian women with metastatic breast cancer.
- #e22193 Samol et al. Combining plasma and tissue next-generation sequencing provides optimal treatment selection for metastatic NSCLC: A comparative study.
Lucence will be attending the ASCO Annual Meeting in Chicago, Illinois. To book a meeting with the Lucence team at ASCO, please visit https://calendly.com/maryjo-mullen/asco23.
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.